- Home
- CMMB vs NOM Comparison
CMMB vs NOM Comparison
Compare CMMB & NOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- NOM
- Stock Information
- Founded
- CMMB 2004
- NOM 1993
- Country
- CMMB Israel
- NOM United States
- Employees
- CMMB N/A
- NOM N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- NOM Investment Managers
- Sector
- CMMB Health Care
- NOM Finance
- Exchange
- CMMB Nasdaq
- NOM Nasdaq
- Market Cap
- CMMB 23.0M
- NOM 25.0M
- IPO Year
- CMMB N/A
- NOM N/A
- Fundamental
- Price
- CMMB $1.32
- NOM $10.75
- Analyst Decision
- CMMB Strong Buy
- NOM
- Analyst Count
- CMMB 2
- NOM 0
- Target Price
- CMMB $8.50
- NOM N/A
- AVG Volume (30 Days)
- CMMB 133.3K
- NOM 6.9K
- Earning Date
- CMMB 05-15-2025
- NOM 01-01-0001
- Dividend Yield
- CMMB N/A
- NOM 3.39%
- EPS Growth
- CMMB N/A
- NOM N/A
- EPS
- CMMB N/A
- NOM N/A
- Revenue
- CMMB N/A
- NOM N/A
- Revenue This Year
- CMMB N/A
- NOM N/A
- Revenue Next Year
- CMMB N/A
- NOM N/A
- P/E Ratio
- CMMB N/A
- NOM N/A
- Revenue Growth
- CMMB N/A
- NOM N/A
- 52 Week Low
- CMMB $0.78
- NOM $8.52
- 52 Week High
- CMMB $2.55
- NOM $10.48
- Technical
- Relative Strength Index (RSI)
- CMMB 50.02
- NOM 55.81
- Support Level
- CMMB $1.22
- NOM $10.40
- Resistance Level
- CMMB $1.38
- NOM $10.69
- Average True Range (ATR)
- CMMB 0.08
- NOM 0.16
- MACD
- CMMB -0.01
- NOM -0.03
- Stochastic Oscillator
- CMMB 40.00
- NOM 74.55
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About NOM Nuveen Missouri Quality Municipal Income Fund
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in United States. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Missouri state income taxes; its secondary investment objective is the enhancement of portfolio value. The fund invests in municipal securities as well as floating rate securities as well as derivatives such as futures, options and swap contracts to the necessary extent. Nuveen Fund Advisors, LLC acts as an investment adviser of the company.